Currently there are relatively few antiviral therapeutics and most with disadvantages. We have developed a new broad-spectrum antiviral approach with the potential to be effective for numerous clinical and priority viruses.
We are excited to announce that we have signed an exclusive license agreement for US patent 7566694, “Anti-Pathogen Treatments,” which is the one and only remaining active patent related to Todd Rider’s original DRACO work. This gives us an excellent IP foundation for work with our compound in the United States.
There are a few questions that seem to come up with almost every extended conversation about Kimer Med and what we're doing. This isn't meant to be an investor disclosure…